This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
by Zacks Equity Research
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
by Zacks Equity Research
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 0.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 56.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 55.5% upside potential for Crinetics Pharmaceuticals, Inc. (CRNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why
by Zacks Equity Research
Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -3.66% and 325.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of 0% and 54.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.